SynthesisBMC public health2008
Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies.
Synthesis in BMC public health, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury.Scientific reports · 2023Pooled it
- Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials.Canadian journal of gastroenterology & hepatology · 2019Pooled it
- Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.Infectious diseases of poverty · 2020Trial
- Robust anti-tubercular profile ofFrontiers in microbiology · 2024Article
- Article
- Tuberculosis in older adults: challenges and best practices in the Western Pacific Region.The Lancet regional health. Western Pacific · 2023Review
- Prevalence, Perception and Predictors of Concomitant Herbal Medicine Use among HIV/AIDS and Tuberculosis Patients in Metekel Zone, Northwest Ethiopia: A Cross-Sectional Study.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.Antimicrobial agents and chemotherapy · 2018Review
- Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity.Tuberculosis and respiratory diseases · 2017Article
- Tuberculosis of the Liver, Biliary Tract, and Pancreas.Microbiology spectrum · 2017Review
- Are tuberculosis patients adherent to prescribed treatments in China? Results of a prospective cohort study.Infectious diseases of poverty · 2016Article
- Are free anti-tuberculosis drugs enough? An empirical study from three cities in China.Infectious diseases of poverty · 2015Article
- An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury.International journal of clinical and experimental medicine · 2015Article
- Is tuberculosis treatment really free in China? A study comparing two areas with different management models.PloS one · 2015Article
- Article
- Article
- Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China.BMC public health · 2012Article
- Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses.PloS one · 2012Article
- ATT- A Double Edged Sword?Indian journal of pharmaceutical sciences · 2011Article
- Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).BMC public health · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrugs to protect the liver are frequently prescribed in some countries as part of treatment for tuberculosis. The biological rationale is not clear, they are expensive and may do harm. We conducted a systematic review to a) describe the ingredients of "liver protection drugs"; and b) compare the evidence base for the policy against international standards.
methodsWe searched international medical databases (MEDLINE, EMBASE, LILACS, CINAHL, Cochrane Central Register of Controlled Trials, and the specialised register of the Cochrane Infectious Diseases Group) and Chinese language databases (CNKI, VIP and WanFang) to April 2007. Our inclusion criteria were research papers that reported evaluating any liver protection drug or drugs for preventing liver damage in people taking anti-tuberculosis treatment. Two authors independently categorised and extracted data, and appraised the stated methods of evaluating their effectiveness.
resultsEighty five research articles met our inclusion criteria, carried out in China (77), India (2), Russia (4), Ukraine (2). These articles evaluated 30 distinct types of liver protection compounds categorised as herbal preparations, manufactured herbal products, combinations of vitamins and other non-herbal substances and manufactured pharmaceutical preparations. Critical appraisal of these articles showed that all were small, poorly conducted studies, measuring intermediate outcomes. Four trials that were described as randomised controlled trials were small, had short follow up, and did not meet international standards.
conclusionThere is no reliable evidence to support prescription of drugs or herbs to prevent liver damage in people on tuberculosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.